Hirtzlin J, Färber P M, Franklin R M, Bell A
Department of Structural Biology, Biozentrum, University of Basel, Switzerland.
Eur J Biochem. 1995 Sep 15;232(3):765-72.
The immunosuppressive drug cyclosporin A (CsA) inhibits the growth of malaria parasites in vitro and in vivo. Cyclosporin A exerts its immunosuppressive effect in T lymphocytes by binding to cyclophilin (CyP), a peptidylprolyl cis-trans isomerase (PPIase). It is believed that the cyclosporin/cyclophilin complex inhibits a Ca(2+)-activated protein phosphatase, calcineurin, involved in T-cell activation. A cDNA encoding a cyclophilin of the human malaria parasite Plasmodium falciparum has been isolated as a step in the elucidation of the mechanism of antimalarial action of CsA. This cDNA, termed PfCyP, encodes a protein of 195 amino acids which has highest similarity with the Candida albicans (73.1%) and the Drosophila melanogaster (73.1%) cytoplasmic cyclophilins. A Northern blot reveals an approximately 900-bp nucleotide transcript that is consistent with the predicted size of the encoded polypeptide. The predicted PfCyP protein has a putative endoplasmic-reticulum-directed signal sequence at its N-terminus and two potential N-linked glycosylation sites. Expression of PfCyP RNA in an in vitro translation/translocation system reveals that the PfCyP protein is translocated across microsomes, that the signal peptide is cleaved and that the PfCyP protein is glycosylated at two sites. The PfCyP cDNA open reading frame coding for the predicted mature protein has been expressed in Escherichia coli. The purified recombinant protein is an active PPIase (kcat/Km = 2.3 x 10(6) s-1 M-1); this enzymic activity is inhibited by CsA (IC50 = 10 nM). The PfCyP protein has thus the same sensitivity to CsA as the PPIase activity associated with P. falciparum extracts [Bell, A. et al. (1994) Biochem. Pharmacol. 48, 495-503] suggesting that PfCyP may be responsible for the PPIase activity in those extracts. If different cyclophilins exist in P. falciparum, we conclude that either the PfCyP protein is the major cyclophilin detected in the parasite or that there are other cyclophilins with similar susceptibilities to CsA.
免疫抑制药物环孢菌素A(CsA)在体外和体内均能抑制疟原虫的生长。环孢菌素A通过与亲环蛋白(CyP)结合发挥其在T淋巴细胞中的免疫抑制作用,亲环蛋白是一种肽基脯氨酰顺反异构酶(PPIase)。据信,环孢菌素/亲环蛋白复合物抑制一种参与T细胞活化的钙激活蛋白磷酸酶——钙调神经磷酸酶。作为阐明CsA抗疟作用机制的一个步骤,已分离出编码人类疟原虫恶性疟原虫亲环蛋白的cDNA。这个被称为PfCyP的cDNA编码一个由195个氨基酸组成的蛋白质,它与白色念珠菌(73.1%)和黑腹果蝇(73.1%)的细胞质亲环蛋白具有最高的相似性。Northern印迹显示一个约900 bp的核苷酸转录本,与预测的编码多肽大小一致。预测的PfCyP蛋白在其N端有一个假定的内质网导向信号序列和两个潜在的N-糖基化位点。PfCyP RNA在体外翻译/转运系统中的表达表明,PfCyP蛋白可转运穿过微粒体,信号肽被切割,且PfCyP蛋白在两个位点发生糖基化。编码预测成熟蛋白的PfCyP cDNA开放阅读框已在大肠杆菌中表达。纯化的重组蛋白是一种活性PPIase(催化常数/米氏常数=2.3×10⁶ s⁻¹ M⁻¹);这种酶活性被CsA抑制(半数抑制浓度=10 nM)。因此,PfCyP蛋白对CsA的敏感性与恶性疟原虫提取物相关的PPIase活性相同[贝尔,A.等人(1994年)《生物化学与药理学》48卷,495 - 503页],这表明PfCyP可能是这些提取物中PPIase活性的原因。如果恶性疟原虫中存在不同的亲环蛋白,我们得出结论,要么PfCyP蛋白是在该寄生虫中检测到的主要亲环蛋白,要么存在其他对CsA敏感性相似的亲环蛋白。